{"id":942951,"date":"2026-03-09T16:03:55","date_gmt":"2026-03-09T20:03:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\/"},"modified":"2026-03-09T16:03:55","modified_gmt":"2026-03-09T20:03:55","slug":"contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\/","title":{"rendered":"Contact Levi &amp; Korsinsky by May 4, 2026 Deadline to Join Class Action Against Aquestive Therapeutics, Inc.(AQST)"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, March  09, 2026  (GLOBE NEWSWIRE) &#8212; Levi &amp; Korsinsky, LLP notifies investors in\u00a0<strong>Aquestive Therapeutics, Inc.<\/strong> (&#8220;Aquestive&#8221; or the &#8220;Company&#8221;) (NASDAQ: AQST) of a class action securities lawsuit.<\/p>\n<p>\n        <strong>CLASS DEFINITION: <\/strong>The lawsuit seeks to recover losses on behalf of Aquestive investors who were adversely affected by alleged securities fraud between June 16, 2025 and January 8, 2026. Follow the link below to get more information and be contacted by a member of our team:<\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4LAQItmhj9e6Htw5vX8UV3860J1_luEcytdJy8VCmjvaF4MzGiUXJ-vNaDrTRS8pauQxpqVeOi-gbNMQXuOVlMOOYBBTTwa3n7LcKkVitICSBndYd9hw_i1arvRm97NRvHbxY3NFPK1xGW6asfnxCPm4qxmKPDZTUV06vPZP6jJXnC7KkGHlJjM5ls5Ul7o94kWR0f9bX9dP5ug-a9LmlcN4w5PgtfB4fIzp4sNXWPg_nlML-UYtI6zD2NWeCMrQBS30AItPcC9DXnsnX0PPj_1U-7djFx-OyCY5HPNWoD8=\" rel=\"nofollow\" target=\"_blank\">https:\/\/zlk.com\/pslra-1\/aquestive-therapeutics-inc-lawsuit-submission-form-4?prid=184149&amp;wire=3<\/a>\n      <\/p>\n<p>\n        <strong>AQST<\/strong> investors may also contact Joseph E. Levi, Esq. via email at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nNEAQzYm7LhWvQ2AOOgmeTcS-u9WW7Yz9anwtSMDhrKCOVM66nRXXbSkc8aJc0ebqmtgfrIaJey0lPcFveBMJZjEhN-pXa74nnAm1p94kH8=\" rel=\"nofollow\" target=\"_blank\">jlevi@levikorsinsky.com<\/a> or by telephone at (212) 363-7500.<\/p>\n<p>\n        <strong>CASE DETAILS: <\/strong>According to the complaint, defendants provided investors with positive statements while, at the same time, disseminating materially false and misleading statements and\/or concealing material adverse facts concerning the true state of Aquestive\u2019s New Drug Application (NDA) for Anaphylm (Dibutepinephrine) sublingual film; pertinently, Aquestive concealed or otherwise minimized the significance of the human factors involved in the use and deployment of its sublingual film, such as packaging, use, administration, and labeling. On January 9, 2026, Aquestive announced that the Company was in receipt of a letter from the FDA identifying deficiencies that precluded labeling discussions for Anaphylm. Moreover, Aquestive revealed that the letter from the FDA confirmed that the Agency\u2019s review of Anaphylm NDA was ongoing and no final decision had been made, which effectively delayed the approval of Anaphylm well beyond the January 31, 2026 Prescription Drug User Fee Act date. Following this news, the price of Aquestive\u2019s common stock declined dramatically. From a closing market price of $6.21 per share on January 8, 2026, Aquestive\u2019s stock price fell to $3.91 per share on January 9, 2026, a decline of over 37% in a single day.<\/p>\n<p>\n        <strong>WHAT&#8217;S NEXT? <\/strong>If you suffered a loss in Aquestive during the relevant time frame, you have until <strong>May 4, 2026<\/strong>\u00a0to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn&#8217;t require that you serve as a lead plaintiff.<\/p>\n<p>\n        <strong>NO COST TO YOU: <\/strong>If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. <strong>There is no cost or obligation to participate.<\/strong><\/p>\n<p>\n        <strong>WHY LEVI &amp; KORSINSKY: <\/strong>Over the past 20 years, the team at Levi &amp; Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi &amp; Korsinsky has ranked in ISS Securities Class Action Services\u2019 Top 50 Report as one of the top securities litigation firms in the United States.<\/p>\n<p>\n        <strong>CONTACT:<\/strong><br \/>\n        <br \/>Levi &amp; Korsinsky, LLP <br \/>Joseph E. Levi, Esq.<br \/>Ed Korsinsky, Esq.<br \/>33 Whitehall Street, 27th Floor<br \/>New York, NY 10004<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nNEAQzYm7LhWvQ2AOOgmeTcS-u9WW7Yz9anwtSMDhrLDf2LKbspxCkmXz0skYhCIoAWck4s-tyIAQ5MfnpXuBenGKal6IuorZs4kNr8u4gM=\" rel=\"nofollow\" target=\"_blank\">jlevi@levikorsinsky.com<\/a><br \/>Tel: (212) 363-7500<br \/>Fax: (212) 363-7171<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cKiYyTDAXo_BiZBr3DmGaSKAiShJfmjqOzNGSaazJJkfozFpzKctNI8dxP9-QR1g4_RWMOAsJ4atV_8dJ1EUnQ==\" rel=\"nofollow\" target=\"_blank\">www.zlk.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NzY3MiM3NDcyNzIxIzIwMjA0MjY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MWQ1YjU5MTktYWJjNS00Mjk2LTk2OTMtZDIwMWYwYTE1MWNhLTEwMzIyOTMtMjAyNi0wMy0wOS1lbg==\/tiny\/Levi-Korsinsky-LLP.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) &#8212; Levi &amp; Korsinsky, LLP notifies investors in\u00a0Aquestive Therapeutics, Inc. (&#8220;Aquestive&#8221; or the &#8220;Company&#8221;) (NASDAQ: AQST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Aquestive investors who were adversely affected by alleged securities fraud between June 16, 2025 and January 8, 2026. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/aquestive-therapeutics-inc-lawsuit-submission-form-4?prid=184149&amp;wire=3 AQST investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, defendants provided investors with positive statements while, at the same time, disseminating materially false and misleading statements and\/or concealing &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Contact Levi &amp; Korsinsky by May 4, 2026 Deadline to Join Class Action Against Aquestive Therapeutics, Inc.(AQST)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-942951","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Contact Levi &amp; Korsinsky by May 4, 2026 Deadline to Join Class Action Against Aquestive Therapeutics, Inc.(AQST) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Contact Levi &amp; Korsinsky by May 4, 2026 Deadline to Join Class Action Against Aquestive Therapeutics, Inc.(AQST) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) &#8212; Levi &amp; Korsinsky, LLP notifies investors in\u00a0Aquestive Therapeutics, Inc. (&#8220;Aquestive&#8221; or the &#8220;Company&#8221;) (NASDAQ: AQST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Aquestive investors who were adversely affected by alleged securities fraud between June 16, 2025 and January 8, 2026. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/aquestive-therapeutics-inc-lawsuit-submission-form-4?prid=184149&amp;wire=3 AQST investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, defendants provided investors with positive statements while, at the same time, disseminating materially false and misleading statements and\/or concealing &hellip; Continue reading &quot;Contact Levi &amp; Korsinsky by May 4, 2026 Deadline to Join Class Action Against Aquestive Therapeutics, Inc.(AQST)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-09T20:03:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NzY3MiM3NDcyNzIxIzIwMjA0MjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Contact Levi &amp; Korsinsky by May 4, 2026 Deadline to Join Class Action Against Aquestive Therapeutics, Inc.(AQST)\",\"datePublished\":\"2026-03-09T20:03:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\\\/\"},\"wordCount\":487,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NzY3MiM3NDcyNzIxIzIwMjA0MjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\\\/\",\"name\":\"Contact Levi &amp; Korsinsky by May 4, 2026 Deadline to Join Class Action Against Aquestive Therapeutics, Inc.(AQST) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NzY3MiM3NDcyNzIxIzIwMjA0MjY=\",\"datePublished\":\"2026-03-09T20:03:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NzY3MiM3NDcyNzIxIzIwMjA0MjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NzY3MiM3NDcyNzIxIzIwMjA0MjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Contact Levi &amp; Korsinsky by May 4, 2026 Deadline to Join Class Action Against Aquestive Therapeutics, Inc.(AQST)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Contact Levi &amp; Korsinsky by May 4, 2026 Deadline to Join Class Action Against Aquestive Therapeutics, Inc.(AQST) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\/","og_locale":"en_US","og_type":"article","og_title":"Contact Levi &amp; Korsinsky by May 4, 2026 Deadline to Join Class Action Against Aquestive Therapeutics, Inc.(AQST) - Market Newsdesk","og_description":"NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) &#8212; Levi &amp; Korsinsky, LLP notifies investors in\u00a0Aquestive Therapeutics, Inc. (&#8220;Aquestive&#8221; or the &#8220;Company&#8221;) (NASDAQ: AQST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Aquestive investors who were adversely affected by alleged securities fraud between June 16, 2025 and January 8, 2026. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/aquestive-therapeutics-inc-lawsuit-submission-form-4?prid=184149&amp;wire=3 AQST investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, defendants provided investors with positive statements while, at the same time, disseminating materially false and misleading statements and\/or concealing &hellip; Continue reading \"Contact Levi &amp; Korsinsky by May 4, 2026 Deadline to Join Class Action Against Aquestive Therapeutics, Inc.(AQST)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-09T20:03:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NzY3MiM3NDcyNzIxIzIwMjA0MjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Contact Levi &amp; Korsinsky by May 4, 2026 Deadline to Join Class Action Against Aquestive Therapeutics, Inc.(AQST)","datePublished":"2026-03-09T20:03:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\/"},"wordCount":487,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NzY3MiM3NDcyNzIxIzIwMjA0MjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\/","name":"Contact Levi &amp; Korsinsky by May 4, 2026 Deadline to Join Class Action Against Aquestive Therapeutics, Inc.(AQST) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NzY3MiM3NDcyNzIxIzIwMjA0MjY=","datePublished":"2026-03-09T20:03:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NzY3MiM3NDcyNzIxIzIwMjA0MjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NzY3MiM3NDcyNzIxIzIwMjA0MjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-levi-korsinsky-by-may-4-2026-deadline-to-join-class-action-against-aquestive-therapeutics-inc-aqst\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Contact Levi &amp; Korsinsky by May 4, 2026 Deadline to Join Class Action Against Aquestive Therapeutics, Inc.(AQST)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942951","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=942951"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942951\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=942951"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=942951"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=942951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}